var data={"title":"E. coli asparaginase (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">E. coli asparaginase (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5672?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=e-coli-asparaginase-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;E. coli asparaginase (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137000\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Kidrolase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137036\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Enzyme;</li>\n      <li>\n        Antineoplastic Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137004\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose, frequency, number of doses, and start date may vary by protocol and treatment phase.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Acute lymphoblastic leukemia (ALL; Canadian labeling): </b> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Daily administration: 200 to 1,000 units/kg/day for 28 consecutive days; continue induction therapy for an additional 14 days if not in remission or begin maintenance therapy if in remission</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermittent administration: 400 units/kg on Monday and Wednesday and 600 units/kg on Friday; repeat for 4 weeks; continue induction therapy for an additional 2 weeks if not in remission or begin maintenance therapy if in remission </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Hyper-CVAD regimen (off-label dosing):</i> IV 20,000 units weekly for 4 doses (starting on day 2) during either months 7 and 19 or months 7 and 11 of intensification phase (Thomas 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Larson regimen (off-label dosing):</i> SubQ: 6000 units/m<sup>2</sup>/dose on days 5, 8, 11, 15, 18, and 22 (induction phase) and on days 15, 18, 22, and 25 (early intensification phase) (Larson, 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Linker regimen (off-label dosing):</i> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Remission induction: 6000 units/m<sup>2</sup>/dose on days 17-28; if bone marrow on day 28 is positive for residual leukemia: 6000 units/m<sup>2</sup>/dose on days 29-35 (Linker, 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Consolidation (Treatment A; cycles 1, 3, 5, and 7): 12,000 units/m<sup>2</sup>/dose on days 2, 4, 7, 9, 11, and 14 (Linker, 1991) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lymphoblastic lymphoma (off-label use):</b> Hyper-CVAD regimen: IV: 20,000 units weekly for 4 doses (starting on day 2) for 2 cycles (months 7 and 11) during maintenance phase (Thomas 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137023\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose, frequency, number of doses, and start date may vary by protocol and treatment phase.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Acute lymphoblastic leukemia (ALL): Children and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>CCG 1922 protocol (off-label dosing):</i>  IM:  6,000 units/m<sup>2</sup>/dose 3 times weekly for 9 doses beginning either on day 2, 3, or 4 (induction phase) and 6,000 units/m<sup>2</sup>/dose on Monday, Wednesday, and Friday for 6 doses beginning day 3 (delayed intensification phase) (Bostrom 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>DFCI-ALL Consortium protocol 00-01 (off-label dosing):</i> IM: 25,000 units/m<sup>2</sup> for 1 dose (induction phase) and 25,000 units/m<sup>2</sup>/dose weekly for 30 weeks (intensification phase) (Vrooman 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>DFCI-ALL Consortium protocol 95-01 (off-label dosing):</i> IM: 25,000 units/m<sup>2</sup> for 1 dose on day 4 (induction phase) and 25,000 units/m<sup>2</sup>/dose weekly for 20 weeks (intensification phase) (Moghrabi 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Hyper-CVAD regimen (off-label dosing):</i> Adolescents &ge;13 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lymphoblastic lymphoma (off-label use):</b> Adolescents &gt;15 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137005\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673217\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673218\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in patients with hepatic insufficiency. The following adjustments have been recommended for hepatotoxicity during treatment (Stock 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ALT/AST &gt;3 to 5 times ULN: Continue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ALT/AST &gt;5 to 20 times ULN: Delay next dose until transaminases &lt;3 times ULN.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ALT/AST &gt;20 times ULN: Discontinue therapy if takes longer than 1 week for transaminases to return to &lt;3 times ULN.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Direct bilirubin &lt;3 mg/dL: Continue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Direct bilirubin 3.1 to 5 mg/dL: Hold asparaginase and resume when direct bilirubin &lt;2 mg/dL; consider switching to alternate asparaginase product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Direct bilirubin &gt;5 mg/dL: Discontinue asparaginase; do not substitute other asparaginase products; do not make up for missed doses. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21287967\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Allergic reaction/hypersensitivity: Discontinue for severe reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Neurotoxicity (posterior reversible encephalopathy syndrome; PRES): Interrupt therapy for suspected PRES; control blood pressure and closely monitor for seizure activity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Pancreatitis: Discontinue permanently (per manufacturer).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Thrombotic event: Discontinue for serious reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">The following adjustments have also been recommended (Stock 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Hyperammonemia-related fatigue:</i> Continue therapy for grade 2 toxicity. If grade 3 toxicity occurs, reduce dose by 25%; resume full dose when toxicity &le; grade 2 (make up for missed doses). If grade 4 toxicity occurs, reduce dose by 50%; resume full dose when toxicity &le; grade 2 (make up for missed doses).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Hyperglycemia:</i> Continue therapy for uncomplicated hyperglycemia. If hyperglycemia requires insulin therapy, hold asparaginase (and any concomitant corticosteroids) until blood glucose controlled; resume dosing at prior dose level. For life-threatening hyperglycemia or toxicity requiring urgent intervention, hold asparaginase (and corticosteroids) until blood glucose is controlled with insulin; resume asparaginase and do not make up for missed doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Hypersensitivity reactions:</i> May continue dosing for urticaria without bronchospasm, hypotension, edema, or need for parenteral intervention. If wheezing or other symptomatic bronchospasm with or without urticaria, angioedema, hypotension, and/or life-threatening hypersensitivity reactions occur, discontinue asparaginase.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Hypertriglyceridemia:</i> If serum triglyceride level &lt;1,000 mg/dL, continue asparaginase but monitor closely for pancreatitis. If triglyceride level &gt;1,000 mg/dL, hold asparaginase and monitor; resume therapy at prior dose level after triglyceride level returns to baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Pancreatitis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Asymptomatic amylase or lipase &gt;3 times ULN (chemical pancreatitis) or radiologic abnormalities only: Continue asparaginase and monitor levels closely.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Symptomatic amylase or lipase &gt;3 times ULN: Hold asparaginase until enzyme levels stabilize or are declining.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Symptomatic pancreatitis or clinical pancreatitis (abdominal pain with amylase or lipase &gt;3 times ULN for &gt;3 days and/or development of pancreatic pseudocyst): Permanently discontinue asparaginase.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Thrombosis and bleeding, CNS:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Thrombosis: Continue therapy for abnormal laboratory findings without a clinical correlate. If grade 3 toxicity occurs, discontinue therapy; if CNS signs/symptoms are fully resolved and further asparaginase doses are required, may resume therapy at a lower dose and/or longer intervals between doses. Discontinue therapy for grade 4 toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Hemorrhage: Discontinue therapy; do not withhold therapy for abnormal laboratory findings without a clinical correlate. If grade 3 toxicity occurs, discontinue therapy; if CNS signs/symptoms are fully resolved and further asparaginase doses are required, may resume therapy at a lower dose and/or longer intervals between doses. Discontinue therapy for grade 4 toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Thrombosis and bleeding, non-CNS:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Thrombosis: Continue therapy for abnormal laboratory findings without a clinical correlate. If grade 3 or 4 toxicity occurs, withhold therapy until acute toxicity and clinical signs resolve and anticoagulant therapy is stable or completed. Do not withhold therapy for abnormal laboratory findings without clinical correlate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Hemorrhage: If grade 2 bleeding in conjunction with hypofibrinogenemia occurs, withhold therapy until bleeding &le; grade 1. Do not withhold therapy for abnormal laboratory findings without clinical correlate. For grade 3 or 4 bleeding, withhold therapy until bleeding &le; grade 1 and until acute toxicity and clinical signs resolve and coagulant replacement therapy is stable or completed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136961\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27259234\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Reconstituted, Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kidrolase: 10,000 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21287977\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">US product, Elspar, was discontinued more than 1 year ago. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136980\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered IM (preferred for intermittent administration) or IV; has been administered SubQ (off-label route; Larson, 1995) in specific protocols. May administer corticosteroids 1 to 2 days prior to initiating reinduction therapy (to prevent hypersensitivity reaction). Observe patients for 1 hour after administration; have epinephrine, diphenhydramine, and hydrocortisone at the bedside. A physician should be readily accessible.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Doses should be given as a deep intramuscular injection into a large muscle; volumes &gt;2 mL should be divided and administered in 2 separate sites.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">IV: Infuse over at least 30 minutes through the side arm of a NS or D<sub>5</sub>W infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136978\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute lymphoblastic leukemia:</b> Treatment of acute lymphoblastic leukemia (ALL) (in combination with other chemotherapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475109\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Lymphoblastic lymphoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137045\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Asparaginase (<i>E. coli</i>) may be confused with asparaginase (<i>Erwinia</i>), pegaspargase </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes boxed warnings. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136968\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Cardiovascular: Cerebrovascular accident (hemorrhagic stroke and thrombotic stroke [Morgan 2011]), thrombosis (including cerebral thrombosis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Central nervous system: Central nervous system disease (adults; includes delusion, disorientation, mild depression, Parkinsonian-like syndrome, personality disorder, seizure), cerebral hemorrhage, cerebrovascular hemorrhage (Morgan 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Endocrine &amp; metabolic: Amenorrhea, decreased glucose tolerance, hyperammonemia (with clinical signs of metabolic encephalopathy [eg, impaired consciousness with coma, confusion, and stupor]), hypercholesterolemia, hyperglycemia, hypertriglyceridemia, hypoalbuminemia, hypocholesterolemia, increased uric acid, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Gastrointestinal: Abdominal pain (infrequent), acute pancreatitis (may be fatal), cholestatic injury, diarrhea (infrequent), intestinal perforation (rare), nausea (frequent, but rarely severe; may be secondary to increased blood urea nitrogen and increased uric acid), vomiting (frequent, but rarely severe; may be secondary to increased blood urea nitrogen and increased uric acid)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Genitourinary: Azoospermia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Hematologic: Antithrombin III deficiency, blood coagulation disorder (change in hemostatic function), bone marrow depression, decreased clotting factors (factors VII, VIII, IX, and X), decreased plasminogen, hypofibrinogenemia, prolonged partial thromboplastin time, prolonged prothrombin time</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Hepatic: Hepatic injury, hepatotoxicity (usually mild and regressive, but may be fatal rarely), hyperbilirubinemia, increased serum alkaline phosphatase, increased serum ALT, increased serum AST (mild), jaundice, liver steatosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Hypersensitivity:  Allergic reactions (includes anaphylactic shock, anaphylaxis, bronchospasm, edema, hypotension, laryngeal edema, skin rash, urticaria; onset usually within 1 hour of administration and risk increasing with increasing number of exposures)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Immunologic: Increased serum globulins (beta and gamma)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Infection: Septicemia (during bone marrow depression)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Renal: Increased blood urea nitrogen, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Respiratory:  Respiratory distress (with retrosternal pressure)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136983\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to asparaginase (<i>E. coli</i>-derived) or any component of the formulation; hepatic insufficiency,  pancreatitis, pregnancy, breast-feeding, recent yellow fever vaccination, concurrent administration with phenytoin </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136965\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic reactions: <b>[Canadian Boxed Warning]: Allergic reactions may occur during therapy, particularly in patients with known hypersensitivity to other forms of L-asparaginase.</b> Observe for reactions following administration; reactions generally occur 30 to 60 minutes following administration (although may also occur beyond that time). Immediate treatment for hypersensitivity reactions should be available during administration. Discontinue if serious allergic reaction occurs. Prior exposure to asparaginase is a risk factor for allergic reactions; IV administration (compared to IM or SubQ administration) and younger age also may be associated with hypersensitivity reactions (Stock 2011; Woo 2000). Patients who have an allergic reaction to <i>E. coli</i> asparaginase may also react to asparaginase (<i>Erwinia</i>) or to pegaspargase. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Coagulopathy: Increased prothrombin time, partial thromboplastin time, and hypofibrinogenemia may occur; cerebrovascular thrombosis and hemorrhage have been reported; monitor coagulation parameters at baseline and periodically during and after therapy. Use with caution in patients with an underlying coagulopathy.  Replacement therapy should be instituted if fibrinogen  &lt;1g/L or ATIII &lt;60%; if ineffective, treatment should preferably be suspended and resumed only when the laboratory parameters have normalized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: <b>[Canadian Boxed Warning]: Adverse effects on liver function may be observed including exacerbation of preexisting liver impairment (due to prior therapy or underlying disease). Physicians should carefully consider therapeutic benefits versus toxicity risks.</b> Altered liver function tests (eg, increased AST, ALT, alkaline phosphatase, bilirubin, and decreased serum albumin, plasma fibrinogen) may occur; fulminant hepatic failure has also occurred. Fatty liver may be observed on biopsy. Use with caution and monitor liver function tests at least weekly during therapy; discontinue therapy for any significant changes. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperammonemia: May induce excessive ammonia production; monitor for signs of metabolic encephalopathy (confusion, stupor, coma).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperglycemia: May cause hyperglycemia/glucose intolerance (may be irreversible); cases of diabetic ketoacidosis have been observed. Monitor blood glucose as clinically necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: Posterior reversible encephalopathy syndrome (PRES) has been observed in patients treated with asparaginase (in combination with other chemotherapy agents). Monitor for signs/symptoms of PRES (eg, altered mental status, headache, hypertension, seizures, visual disturbances); interrupt therapy for suspected PRES. Control blood pressure and closely monitor for seizure activity. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: May cause serious and possibly fulminant or fatal pancreatitis; promptly evaluate patients with abdominal pain. May consider continuing therapy for asymptomatic chemical pancreatitis (amylase or lipase &gt;3 times ULN) or only radiologic abnormalities; monitor closely for rising amylase and/or lipase levels (Stock 2011). Discontinue permanently for clinical pancreatitis (eg, vomiting, severe abdominal pain) with amylase/lipase elevation &gt;3 times ULN for &gt;3 days and/or development of a pancreatic pseudocyst. Avoid alcohol use (Stock 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombotic events: Serious thrombosis, including sagittal sinus thrombosis may occur; discontinue with serious thrombotic events. Anticoagulation prophylaxis during therapy may be considered in some patients (Farge 2013). The risk for thrombosis may be higher in adult patients (Stock 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tumor lysis syndrome: Appropriate measures must be taken to prevent tumor lysis syndrome and subsequent hyperuricemia and uric acid nephropathy; monitor, consider antihyperuricemic therapy, hydration and urinary alkalization.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: <b>[Canadian Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician in a setting where full resuscitative facilities are immediately available.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Medication error prevention: Do not interchange <i>E. coli</i> asparaginase for <i>Erwinia</i> asparaginase or pegaspargase; ensure the proper formulation, route of administration, and dose prior to administration. The <i>E. coli</i> and the <i>Erwinia</i> strains of asparaginase differ slightly in their gene sequencing, and have slight differences in their enzyme characteristics. Both are highly specific for asparagine and have &lt;10% activity for the D-isomer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298780\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136970\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8901&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): Asparaginase (E. coli) may increase the serum concentration of Dexamethasone (Systemic). This is thought to be due to an asparaginase-related decrease in hepatic proteins responsible for dexamethasone metabolism. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136986\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136975\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, amylase, lipase, triglycerides, liver function prior to and weekly during therapy, coagulation parameters (baseline and prior to each injection),  blood glucose, uric acid. Monitor for allergic reaction; monitor for onset of abdominal pain and mental status changes. Monitor vital signs during administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136964\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">In leukemic cells, asparaginase hydrolyzes L-asparagine to ammonia and L-aspartic acid, leading to depletion of asparagine. Leukemia cells, especially lymphoblasts, require exogenous asparagine; normal cells can synthesize asparagine. Asparagine depletion in leukemic cells leads to inhibition of protein synthesis and apoptosis. Asparaginase is cycle-specific for the G<sub>1</sub> phase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136982\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: IV: Slightly higher than plasma volume;  &lt;1% CSF penetration </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Systemically degraded </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IM: 34 to 49 hours; IV: 8 to 30 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: IM: 14 to 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136987\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Asparaginase medac (PL);</li>\n      <li>Colaspase (JO);</li>\n      <li>Crasnitin (AT, CH, HN, PT);</li>\n      <li>Elspar (BR, MX);</li>\n      <li>Kidrolase (AE, AR, BG, CO, EG, FR, IL, LB, PE, PL, QA, UY);</li>\n      <li>L-aspase (PH);</li>\n      <li>Laspar (ZA);</li>\n      <li>Leucoginase (LK);</li>\n      <li>Leunase (AU, BD, CN, HK, ID, IN, JP, KR, MY, NZ, PK, SG, TH, TW, VN);</li>\n      <li>Oncaspar (DE);</li>\n      <li>Onconase (LK);</li>\n      <li>Paronal (BE, NL);</li>\n      <li>Spectrila (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bostrom BC, Sensel MR, Sather HN, et al, &ldquo;Dexamethasone Versus Prednisone and Daily Oral Versus Weekly Intravenous Mercaptopurine for Patients With Standard-Risk Acute Lymphoblastic Leukemia: A Report from the Children's Cancer Group,&rdquo; <i>Blood</i>, 2003, 101(10):3809-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/e-coli-asparaginase-united-states-not-available-drug-information/abstract-text/12531809/pubmed\" target=\"_blank\" id=\"12531809\">12531809</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, &ldquo;Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients,&rdquo; <i>Pediatr Blood Cancer</i>, 2011, 57(2):191-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/e-coli-asparaginase-united-states-not-available-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elspar (L-asparaginase) [prescribing information], Deerfield, IL: Lundbeck; July 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farge D, Debourdeau P, Beckers M, et al, &ldquo;International Clinical Practice Guidelines for the Treatment of and Prophylaxis of Venous Thromboembolism in Patients With Cancer,&rdquo; <i>J Thromb Haemost</i>, 2013, 11(1):56-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/e-coli-asparaginase-united-states-not-available-drug-information/abstract-text/23217107/pubmed\" target=\"_blank\" id=\"23217107\">23217107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidrolase (L-asparaginase) [product monograph]. Montreal, Quebec, Canada: CGF Pharmatec; April 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larson RA, Dodge RK, Burns P, et al, &ldquo;A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,&rdquo; <i>Blood</i>, 1995, 85(8):2025-37.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larson RA, Dodge RK, Linker CA, et al, &quot;A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111,&quot; <i>Blood</i>, 1998, 92(5):1556-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/e-coli-asparaginase-united-states-not-available-drug-information/abstract-text/9716583/pubmed\" target=\"_blank\" id=\"9716583\">9716583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linker CA, Levitt LJ, O'Donnell M, et al, &ldquo;Treatment of Adult Acute Lymphoblastic Leukemia With Intensive Cyclical Chemotherapy: A Follow-up Report,&rdquo; <i>Blood</i>, 1991 78(11):2814-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/e-coli-asparaginase-united-states-not-available-drug-information/abstract-text/1835410 /pubmed\" target=\"_blank\" id=\"1835410 \">1835410 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. <i>Blood</i>. 2007;109(3):896-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/e-coli-asparaginase-united-states-not-available-drug-information/abstract-text/17003366/pubmed\" target=\"_blank\" id=\"17003366\">17003366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo; <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/e-coli-asparaginase-united-states-not-available-drug-information/abstract-text/21276754/pubmed\" target=\"_blank\" id=\"21276754\">21276754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pession A, Valsecchi MG, Masera G, et al, &ldquo;Long-Term Results of a Randomized Trial on Extended Use of High Dose L-Asparaginase for Standard Risk Childhood Acute Lymphoblastic Leukemia,&rdquo; <i>J Clin Oncol</i>, 2005, 23(28):7161-7. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stock W, Douer D, DeAngelo DJ, et al, &ldquo;Prevention and Management of Asparaginase/Pegasparaginase-Associated Toxicities in Adults and Older Adolescents: Recommendations of an Expert Panel,&rdquo; <i>Leuk Lymphoma</i>, 2011, 52(12):2237-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/e-coli-asparaginase-united-states-not-available-drug-information/abstract-text/21827361/pubmed\" target=\"_blank\" id=\"21827361\">21827361</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15178574\"></a>Thomas DA, O'Brien S, Cortes J, et al, &ldquo;Outcome With the Hyper-CVAD Regimens in Lymphoblastic Lymphoma,&rdquo; <i>Blood</i>, 2004, 104(6):1624-30. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/e-coli-asparaginase-united-states-not-available-drug-information/abstract-text/15178574 /pubmed\" target=\"_blank\" id=\"15178574 \">15178574 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas DA, O'Brien S, Faderl S, et al, &ldquo;Chemoimmunotherapy With a Modified Hyper-CVAD And Rituximab Regimen Improves Outcome in <i>de novo</i> Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia,&rdquo; <i>J Clin Oncol</i>, 2010, 28(24):3880-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/e-coli-asparaginase-united-states-not-available-drug-information/abstract-text/20660823/pubmed\" target=\"_blank\" id=\"20660823\">20660823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Vrooman LM, Stevenson KE, Supko JG, et al, &ldquo;Postinduction Dexamethasone and Individualized Dosing of <i>Escherichia Coli</i> L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01,&rdquo; <i>J Clin Oncol</i>, 2013, 31(9):1202-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/e-coli-asparaginase-united-states-not-available-drug-information/abstract-text/23358966/pubmed\" target=\"_blank\" id=\"23358966\">23358966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Woo MH, Hak LJ, Storm MC, et al, &ldquo;Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia,&rdquo; <i>J Clin Oncol</i>, 2000, 18(7):1525-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/e-coli-asparaginase-united-states-not-available-drug-information/abstract-text/10735901/pubmed\" target=\"_blank\" id=\"10735901\">10735901</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8901 Version 125.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F137000\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F137036\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F137004\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F137023\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F137005\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15673217\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673218\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F21287967\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F136961\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F27259234\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F21287977\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F136980\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F136978\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475109\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F137045\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136968\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F136983\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F136965\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298780\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F136970\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F136986\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F136975\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F136964\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F136982\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F136987\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8901|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=e-coli-asparaginase-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">E. coli asparaginase (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}